AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: arnie h who wrote (1780)	12/26/2003 1:07:52 PM
From: richardred	Read Replies (1) of 2173

I took a chance that approval was at hand and lost my gamble, but IMO all is not lost. I think the FDA is being extra cautious here, and rightly so. I have read diabetes is fourth leading cause of death in the United States. As to the disclosure issue, I understand it's an an Informal inquiry. I would hope that companies, especially drug companies, learned something from the Imclone debacle. I think both Mr. Cook and Ms. Graham left on good terms and have a good relationship with Lilly. They both worked there previously , Mr. Cook for 23 at Lilly. The fact AMLN has a collaboration agreement with them on growth factor Humatrope and yet to be approved exenatide singles this out. I still feel this company is reasonably priced due to it's steady decline since Sept. This based on my opinion Symilin will ultimately be approved, and it's potential. Symilin is to important a product for investors to ignore. As to when,your guess is as good as mine. I do know the risk however, if it is found out that new trials might be needed for approval. If this be the case. It will not be taken to kindly on the stock price. GITY-good investing to you

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next